WHAT IS CLAIMED:

1. A method for administration of a substance to a subject's skin comprising delivering the substance into an intradermal compartment of the subject's skin, wherein the substance results in an immune response no greater than when the substance is delivered intramuscularly.

2. A method for administration of a substance to a subject's skin comprising delivering the substance into an intradermal compartment of the subject's skin, wherein the substance results in an immune response no greater than when the substance is delivered subcutaneously.

3. A method for administration of a substance to a subject's skin comprising delivering the substance into an intradermal compartment of the subject's skin, wherein the substance elicits an immune response that is lower than immune response generated when the substance is administered to the intramuscular or subcutaneous compartment of the subject's skin.

4. A method for administration of a substance to a subject's skin comprising delivering the substance into an intradermal compartment of the subject's skin, wherein the substance elicits an immune response that is of the same type as that generated when the substance is administered to the intramuscular or subcutaneous compartment of the subject's skin.

5. A method for administration of a substance to a subject's skin comprising delivering the substance into an intradermal compartment of the subject's skin, wherein the substance elicits an immune response that is of a different type as that generated when the substance is administered to the intramuscular or subcutaneous compartment of the subject's skin.

6. The method of any of claims 1-5, wherein the substance is a therapeutic or diagnostic substance.

7. The method of any of claims 1-5, wherein the therapeutic substance is a chemokine, cytokine or an immunomodulatory agent.

8. The method of any of claims 1-5, wherein the cytokine is interferon.

9. The method of any of claims 1-5, wherein the interferon is interferon-α, interferon-β, or interferon-γ.

10. A method for treating or preventing multiple sclerosis in a subject comprising delivering a therapeutically or prophylactically effective amount of an IFN-β formulation to an intradermal compartment of the subject's skin.

11. The method of any of claims 1-5, wherein the substance is administered at least once a week over a time period of at least 4 weeks, at least 6 weeks, at least 2 months, or up to the life time of the subject.

12. The method of any of claims 1-5, wherein the substance is administered at least twice a week over a time period of at least 4 weeks, at least 6 weeks, at least 2 months, or up to the life time of the subject.

13. The method of any of claims 1-5, wherein the substance is administered through at least one small gauge needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin at a depth of between 0.3 mm and 2 mm, such that administration occurs at a depth between 0.3 mm and 2 mm.